August 2015 | OncologyLive

Outside the Comfort Zone

August 21, 2015

For oncology specialists, caring for patients with cancer has long meant analyzing the biological and clinical pieces of a puzzle unique to each individual and then figuring out the optimal management plan to meet his or her needs.

Effort to "Harmonize" PD-L1 Assays Launched in NSCLC

August 14, 2015

Amid continuing excitement over the potential for immunotherapies targeting the PD-1/PD-L1 pathway, two major questions have loomed over PD-L1 expression levels as a biomarker for this emerging new class of drugs.

Immunotherapy May Hold the Key to Attacking HPV-Associated Cancers

August 14, 2015

An improved understanding of the natural history of HPV, its interaction with the host immune system, and the distinct molecular alterations underlying HPV-positive cancers, are fueling development of new drugs, particularly immunotherapies geared toward generating an HPV-specific immune response.

Oncologists Urged to Help Obese Breast Cancer Patients Manage Weight

August 12, 2015

There is clear evidence that obesity at the time of diagnosis of operable breast cancer is associated with an increased risk of distant recurrence, specifically for HR–positive, HER2-negative disease, and oncologists should consider helping patients better manage their weight as part of their treatment plans.

O'Shaughnessy Details Strategies to Strengthen ER Blockade in MBC

August 11, 2015

Combining estrogen receptor blockade with targeted cell-cycle inhibitors increases therapeutic options for postmenopausal women with ER-positive, HER2-negative metastatic breast cancer, contributing to an evolving paradigm that is moving new regimens to the forefront of the treatment timeline.

A Trendsetter in Oncology Drug Field Draws Inspiration From Patients

August 05, 2015

Howard A. "Skip" Burris III, MD, has helped launched many widely used anticancer therapies by designing and helping to implement first-in-human studies and by leading advanced clinical trials of promising drugs. He was honored in the Drug Development category with a 2014 Giants of Cancer Care® award.

"N-of-1" Research Findings Belong in the Peer-Reviewed Publishing Realm

August 04, 2015

A trend in the biomedical industry to bypass the rigors of scientific publishing was highlighted recently in a provocative commentary regarding the virtual absence of data in the peer-reviewed literature demonstrating the utility of a novel proprietary laboratory testing platform.

Study Adds Pembrolizumab to Paradigm for Certain Head and Neck Cancers

July 24, 2015

A group of researchers at Washington University in St. Louis recently opened a clinical trial to evaluate pembrolizumab as treatment intensification therapy for patients with high-risk locoregionally advanced, previously untreated, HPV-negative head and neck squamous cell carcinomas.